US FDA approves expanded use of J&J's cancer cell therapyFDA allowed the expanded use of Johnson and Johnson Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.
Last Updated IST
The Johnson & Johnson logo.
Credit: Reuters Photo
The US Food and Drug Administration on Friday allowed the expanded use of Johnson and Johnson Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.